About Triskel

Triskel Integrated Services is a privately-owned independent pharmaceutical consultancy based in Switzerland. Triskel assists clients in crafting the most efficient and time- and cost-effective strategies to steer a molecule from discovery to the market.
Over the last 19 years, we have provided strategic consulting to over 88 pharmaceutical companies to develop and obtain 32 marketing authorisations for recombinant proteins, monoclonal antibodies, peptides, extracted biologics, vaccines and new chemical entities.
Triskel was founded in 1995, the same year that the European Medicines Agency (EMA) was established. Coincidentally, the first product ever approved by the EMA in 1995, Gonal-F, was essentially developed by Triskel's founder, Jean-Yves le Cotonnec. Since then, Triskel's team of highly-experienced scientists has contributed to the successful registration and marketing of innovative medicinal products in Europe (centralised procedure), USA, Australia, Canada, Japan, Mexico, Sweden and Switzerland.
Based on a thorough understanding of cutting edge science and the constantly evolving regulatory environment, Triskel forges innovative development plans, advises on best practices in process development and manufacturing, and pioneers effective regulatory strategies for worldwide registration. Triskel has become specialised in the development of biopharmaceuticals presented with a variety of novel scientific and regulatory issues.
Triskel is familiar with differences in EU, US and Japanese regulatory requirements and can prospectively design a development programme to allow entry to all markets without duplication of effort, in addition to providing advice on bringing products to the EU after an overseas-focused development, or vice versa.
Triskel provides a strategic complement to contract research organisations (CROs), contract manufacturers (CMOs) or other classical service providers, offering consulting services throughout the product's lifespan – from discovery through to the post-authorisation phase. Our expertise extends to providing strategic input and to the meticulous preparation of all regulatory documents and reports necessary for successful registration and marketing worldwide.
Our client portfolio, which has grown consistently, includes virtual and start-up companies as well as large publicly-traded multinational pharmaceutical firms in Europe, North America and Asia.
Since its foundation, Triskel has provided services for :
  • 48 non mAb recombinant proteins (of which 8 biosimilars)
  • 31 mAbs (of which 12 biosimilars)
  • 13 peptides
  • 10 vaccines
  • 14 extracted biologics
  • 6 cell based medicinal products
  • 22 new chemical entities